Table 1.
Baseline characteristics of renal transplant recipients with IgA nephropathy as underlying disease leading to TX and their donors in the study population
| Recipient and donor baseline characteristics | All patients (n = 161) | R group (n = 43) | NR group (n = 118) |
|---|---|---|---|
| Median age at TX (years) [IQR] | 48 [38, 60] | 39 [30, 53] | 50 [42, 61] |
| Female, N (%) | 28 (17.4%) | 10 (23.3%) | 18 (15.3%) |
| Caucasian, N (%) | 148 (91.9%) | 37 (86%) | 111 (94.1%) |
| History of prior kidney TX, N (%) | 22 (13.7%) | 7 (16.3%) | 15 (12.7%) |
| KRT prior to TX, N (%) | |||
| - hemodialysis | 95 (59%) | 25 (58.1%) | 70 (59.3%) |
| - peritoneal dialysis | 28 (17.4%) | 7 (16.3%) | 21 (17.8%) |
| - pre-emptive TX | 38 (23.6%) | 11 (25.6%) | 27 (22.9%) |
| Immunosuppression immediate before TX, N (%) | 18 (11.2%) | 5 (11.6%) | 13 (11%) |
| Median age at donation [IQR] | 53 [42, 62] | 49 [42, 58] | 55 [42, 63] |
| Female donors, N (%) | 85 (52.8%) | 25 (58.1%) | 60 (50.8%) |
| Living donation, N (%) | 95 (59%) | 26 (60.5%) | 69 (58.5%) |
| - from relatives | 62 (65.3%) | 17 (65.4%) | 45 (65.2%) |
| Peri-transplant information | |||
| Early allograft dysfunction, N (%) | 15 (9.3%) | 2 (4.7%) | 13 (11%) |
| Median cold ischemia time (hours) [IQR] | 2.1 [1.2, 9.8] | 1.5 [1.1, 10.7] | 2.2 [1.3, 9.1] |
| Induction therapy with ATG/Thymoglobulin, N (%) | 26 (16.1%) | 8 (18.6%) | 18 (15.3%) |
| Immunosuppressive regimen, N (%) | |||
| - TAC-based | 135 (83.9%) | 41 (95.3%) | 94 (79.7%) |
| - Others | 26 (16.1%) | 2 (4.7%) | 24 (20.3%) |
| Presence of HLA antibodies, N (%) | 74 (46%) | 23 (53.5%) | 51 (43.2%) |
| Presence of DSA, N (%) | 20 (12.4%) | 7 (16.3%) | 13 (11%) |
| - Class I | 5 (25%) | 1 (14.3%) | 4 (30.8%) |
| - Class II | 11 (55%) | 2 (28.6%) | 9 (69.2%) |
| - Class I + II | 4 (20%) | 4 (57.1%) | 0 (0%) |
| HLA full match, N (%) | 13 (8.1%) | 3 (7%) | 10 (8.5%) |
| Mean number of HLA A/B/DR mismatch [min, max] | 3.8 [1, 6] | 3.7 [1, 6] | 3.8 [1, 6] |
| CMV high-risk constellation (D+/R-), N (%) | 19 (11.8%) | 6 (14%) | 13 (11%) |
| Administration of RAAS blockade (ACE inhibitor, ARB), N (%) | 55 (34.2%) | 17 (39.5%) | 38 (32.2%) |
Abbreviations:TX transplantation, IQR interquartile range, R/NR recurrence/non-recurrence, KRT kidney replacement therapy, IQR interquartile range, ATG anti-thymocyte globulin, TAC tacrolimus based therapy as combination of prednisone, tacrolimus and mycophenolate mofetil (MMF), HLA human leukocyte antigen, DSA donor specific antibodies, CMV cytomegalovirus, D+ seropositive donor, R- seronegative recipient, RAAS renin-angiotensin-aldosterone system, ACE angiotensin-converting-enzyme, ARB angiotensin receptor blockers